eClinicalMedicine

ObjectivesRespiratory Syncytial Virus (RSV) vaccine policies have varied globally since their approval in 2023. In the UK, policy has adapted in line with National evidence generation such that from Autumn 2026 at-risk persons [&ge;]65 years old will become eligible for vaccination. Immunosuppressed persons <65 years will still not be offered protection. The objective of this study is to investigate the relative burden of RSV infection by age and immunosuppressed status (IC). DesignRetrospective observational cohort study using routine healthcare data from North West London Integrated Care System. ParticipantsPatients with a confirmed diagnosis of a respiratory viral infection (RSV, Influenza A and B, SARS-CoV2) between October 2021 and July 2025. Main outcomes measuresPrevalence and severity of RSV infection in immunosuppressed persons <65 years old, and to provide a comparative analysis with Influenza and SARS-CoV2 in a sub-cohort tested using a 4-in-1 combined rapid PCR test. ResultsDuring the study period, 1226 patients were diagnosed with RSV of whom 596 (48.6%) were <65 years old. In 1091 patients with clinical data, 341 (31.3%) were IC. Fifty (9.9%) patients <65 years old had severe infection (ICU admission or death within 28 days of diagnosis), of whom 14 (28.0%) were IC. Proportionally, 16.7% of all RSV-associated deaths and 55.1% of all ICU RSV-admissions occurred in adult patients <65 years old. RSV accounted for 665 (10.1%) infections confirmed by 4-in-1 viral PCR testing. Eight-nine (13.4%), 172 (9.3%) and 448 (12.0%) patients with RSV, Influenza A and SARS-COV2 experienced severe infection, of whom 32 (36.0%), 82 (47.7%) and 156 (34.8%) were <65 years old respectively. Eight (25.0%), 20 (24.4%) and 52 (33.3%) of patients <65 years old with severe infection were IC. On adjusted analysis, having an immunosuppressive condition increased the odds of a severe SARS-CoV2 infection, OR (95% CI) 1.36 (1.08-1.71) but not a severe RSV or Influenza infection. ConclusionsSevere RSV infections occur in persons <65 years old, with a significant proportion of patients having an immunosuppressive condition. Urgent research is needed to investigate the potential benefit of extending the current UK RSV vaccine policy to protect younger immunosuppressed adults.

Background/Objectives: Older adults are at high risk of influenza-related severe disease and complications. HD-IIV, currently recommended for adults [&ge;]65 years, is egg-based and may be subject to egg-adapted mutations. An mRNA-based vaccine for influenza, mRNA-1010, has been approved by the Food and Drug Administration. Given the clinical benefits observed in mRNA-1010 clinical trials and potential to avoid egg-adapted mutations, this analysis explores the clinical impact of mRNA-1010 compared to HD-IIV in those [&ge;]65 years in the United States. Methods: This study used a decision-analytic model of influenza infection and downstream outcomes to project influenza burden with each vaccine over a one-year timeframe. Vaccine coverage, HD-IIV vaccine effectiveness (VE) and influenza epidemiology was estimated based upon Centers for Disease Control and Prevention data. The relative VE (rVE) for mRNA-1010 vs. HD-IIV was modelled based on data from the clinical trial and published literature on the impact of egg adaptation. Results: The base-case analysis suggests mRNA-1010 may prevent an additional 232,200 symptomatic influenza infections, 130,000 outpatient cases, 21,100 influenza-related hospitalizations, and 2,200 influenza-related deaths compared to HD-IIV. The number needed to vaccination to prevent one hospitalization was 514 or mRNA-1010 vs no vaccine and 404 for HD-IIV versus no vaccine, for an incremental NNV of 110. Scenario and deterministic sensitivity analyses results indicate that clinical outcomes prevented by mRNA-1010 are most sensitive to influenza incidence and VE. Conclusions: mRNA-1010 may improve protection against influenza in US adults aged [&ge;]65 years, leading to meaningful reductions in the clinical influenza-related disease burden in older adults.

Nicotinamide riboside (NR), an endogenous precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+), is characterized as safe and effective for longitudinally elevating NAD+ in blood and tissues, when administered orally. Interest in alternative routes of administration of NR has increased in recent years and led to the development of pharmaceutical-grade NR for intravenous and injectable administration. To evaluate the safety and efficacy of repeat daily injections of NR, an open-label, pilot, trial was initiated. Utilizing a 2x2 parallel study design, 39 study participants were randomized to intramuscular (IM) or subcutaneous (SC) injection administration, and 50 or 100 mg of NR, for 3 consecutive days, followed by a 7-day washout (50 mg IM, n=7; 100 mg IM, n=11; 50 mg SC, n=11; and 100 mg SC, n=10). To assess the primary outcome of safety, vitals, blood biomarkers, and adverse event monitoring were employed. Additional assessments included NAD+ pharmacokinetics and subjective participant-reported outcomes. Daily injections of NR were well tolerated and did not result in any unexpected adverse events or experiences. Pain and muscle soreness/tightness more than two minutes after the injection were reported by 44% and 41% of the participants, respectively, regardless of the route of administration or dose. Significant heterogeneity of pharmacokinetic parameters for NAD+ augmentation of whole blood was observed, however an average of the daily percentage increases in NAD+ was consistent across treatment groups, resulting in 9.51, 9.97, 7.83, and 9.05% for 50 mg IM, 100 mg IM, 50 mg SC, and 100 mg SC, respectively. Exploratory participant-reported outcomes suggest potential benefits on fatigue and sleep, with mixed effects on global physical health. Repeat daily injections of NR were well tolerated, and findings warrant investigation in larger, powered, placebo-controlled trials.

Background: The C-reactive protein-albumin-lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune function. We evaluated its association with survival in primary lung malignancies. Methods: Embase, PubMed, Scopus, and Web of Science were searched from inception to 18 September 2026. Risk of bias was assessed using the Quality In Prognosis Studies tool. Hazard ratios (HRs) were synthesized using random-effects models with restricted maximum likelihood estimation and Hartung-Knapp adjustment. Sensitivity analyses, subgroup analyses, and meta-regression examined robustness and heterogeneity. Results: Eleven studies contributed 13 cohorts to the overall survival (OS) analysis and 8 cohorts from seven studies to a combined recurrence/progression-free survival (RFS/PFS) analysis. Lower CALLY was associated with poorer OS (HR 1.78, 95% CI 1.49-2.12; I2=71.6%) and poorer RFS/PFS (HR 1.60, 95% CI 1.40-1.84; I2=0%). Associations persisted in leave-one-out analyses. No statistically significant subgroup differences were detected. Funnel-plot asymmetry suggested small-study effects for OS and RFS/PFS. Seven studies had moderate and four had high overall risk of bias. The certainty of evidence was rated as low for both OS and RFS/PFS, primarily due to risk of bias, heterogeneity, and endpoint indirectness. Conclusion: Lower CALLY was associated with adverse survival outcomes in the current synthesis. Methodological limitations and variation in biomarker measurement and endpoint definitions restrict interpretation. Prospective validation using standardized measurements and clinically coherent outcomes is needed to establish incremental prognostic value and clinical utility. Keywords: CALLY index; lung cancer; prognosis; overall survival; systematic review; meta-analysis

BackgroundSub-Saharan Africa (sSA) faces accelerated growth in Alzheimers disease and related dementias (ADRDs), including in older people living with HIV (PLWH). However, there are limited contextually relevant diagnostic tools to assess cognitive impairment in the region. The Tablet-based Cognitive Assessment Tool (TabCAT) is a digital platform hosting cognitive tests with automated scoring that can be administered by non-specialists and are designed for use across diverse cultures, languages, and education levels. We translated, adapted, and assessed the validity of a brief battery of TabCAT tests in the Uganda Aging and Dementia Cohort Study (UADCS), a prospective cohort of older PLWH and age- and sex-similar adults not living with HIV in southwestern Uganda. MethodsFour TabCAT tests were translated and culturally adapted through expert review and focus groups of adults at study sites. Psychometric validity was examined by assessing floor and ceiling effects, association with known demographic predictors, and concurrent and divergent validity against a reference-standard cognitive testing battery previously validated and employed in Uganda. Z-scores on all tests were derived using a regression-based normative approach to adjust for age, sex, education, urbanicity, and literacy. Receiver Operating Characteristic (ROC) curves were fit to assess the TabCAT Composite Score performance in discriminating objective cognitive impairment (defined using Jak/Bondi criteria) in the total sample, then stratified by HIV serostatus. ResultsTabCAT tests were reported by local experts and focus groups to have acceptable face and content validity. Participants (n=563, mean age 60{+/-}6.4, 50% female, 51% did not complete primary school, 16% were not literate, 49% PLWH) completed the reference-standard and TabCAT battery. For TabCAT tests, there were no notable floor or ceiling effects, and test scores were associated with age and education as expected. Correlations between TabCAT and reference-standard tests were stronger in aligning cognitive domains (memory, executive function) than in non-aligning domains (motor). The TabCAT Composite Score discriminated cognitive impairment with good performance (c-statistic 0.77; 95% CI 0.72-0.81), including among PLWH. DiscussionTabCAT tests demonstrated face, content, construct, concurrent, and criterion validity for measuring cognition and detecting objective cognitive impairment among older adults in Uganda, including PLWH. These results support the potential of tablet-based brief cognitive assessment tools to measure cognitive performance and detect cognitive impairment in Uganda, including among older PLWH, and in populations with lower levels of education and literacy.

Background: Severe hepatotoxicity has been reported when sotorasib follows immune checkpoint inhibitor (ICI) therapy, and fixed washout intervals have been proposed. We assessed prior ICI exposure and the ICI-to-sotorasib interval as separate risk factors. Materials and methods: We searched PubMed, Europe PMC, Embase, Web of Science, Scopus, CENTRAL, and meeting proceedings for comparative studies of grade 3 or higher hepatotoxicity after KRAS G12C inhibitors. Matched risk ratios (RRs) and unadjusted cohort data were synthesized separately, the latter with an exact conditional odds ratio (OR). Certainty was rated with GRADE. Results: Of 530 unique records screened, seven sources were included, all involving sotorasib. In the only matched analysis (meeting abstract, 386 patients per arm), prior ICI exposure was associated with higher risk (13.2% vs 4.4%, RR 3.00, 95% CI 1.76-5.10), whereas matched comparisons at 6 weeks (RR 1.11, 0.61-2.03) and 12 weeks (RR 1.08, 0.52-2.27) detected no difference but could not exclude important effects. All five unadjusted cohorts showed higher risk with shorter intervals, including 21/74 versus 8/75 patients in the earlier versus later interval quartiles of the CodeBreaK 200 trial, although effect sizes were heterogeneous (exact homogeneity P=0.006). Certainty was very low throughout. Conclusions: Prior ICI exposure was associated with higher risk of severe sotorasib-associated hepatotoxicity, with very low certainty. A shorter interval was associated with higher risk in unadjusted data only, and current evidence does not establish a mandatory washout period. Liver-test monitoring per the prescribing information applies to all patients, whereas additional surveillance after ICI exposure remains an untested precaution.

Background: TB vaccine development is hampered by the natural history of M. tuberculosis: most infected people rarely progress to disease, so trials must be very large and long to accrue sufficient disease endpoints. Current trials enrol IGRA-positive participants (IGRA: Interferon-Gamma Release Assays), but IGRAs remain positive for many years and cannot distinguish recent from remote infection. Tests for recent infection are now in development, and we argue they could make trials substantially more efficient. Here, we investigate how screening participants prior to enrolment with a test for recent M.tb infection could impact the total number of enrollees required for an adequately-powered TB vaccine trial. Methods: Using a statistical model of vaccine trial recruitment, we estimated the number needed to contact, test, and enrol to achieve an 'effective' trial (defined as 50 disease endpoints), under IGRA-gated enrolment (life-long duration of positivity) vs. enrolment with a test for recent infection. We considered five recruitment strategies: non-test-based enrolment for ages 15-49, ages 12-34, and household contacts of recent cases; and test-based enrolment using IGRA, and a test for recent infection with two-year duration of positivity. The model explored trial recruitment in South Africa, Kenya, and India. Results: Compared with an extended-positivity test, a test for recent infection reduced the median number needed to enrol by 4.2- to 6-fold under favourable conditions. It also outperformed non-test-based strategies, including enrolling household contacts. This comes at the cost of substantially more testing, but crude estimates suggest recency-based enrolment would still be cheaper overall provided the new test does not cost more than roughly 5-10 times an IGRA. Conclusions: Diagnostics for recent M.tb infection have the potential to improve vaccine trial efficiency, but more research is now needed to understand test characteristics and to evaluate their use in this setting. Our Viewpoint sets out the test attributes that would need to be established, such as time to positivity, duration of positivity, sensitivity, and specificity, before such tests could be used in vaccine trials.

Introduction: Lichen sclerosus (LS) is a chronic inflammatory dermatosis predominantly affecting the anogenital region of both women and men. Sexual dysfunction remains among the most debilitating and overlooked consequences of the disease, as available patient-reported outcome measures are either restricted to one sex or capture sexual health only partially. The aim of the present work is to validate the Qualisex questionnaire (in its the Italian version) in patients with LS and to evaluate its psychometric properties, factor structure, convergent, discriminant validity, and sex symmetry. Methods: A cross-sectional study was conducted on 211 patients (167 women, 44 men; mean age 52.9 years) with a confirmed diagnosis of LS. Participants completed the Italian Qualisex, Skindex-29, DASS-21, and sexual-health-specific scales, the Female Sexual Function Index (FSFI) for women, and the International Index of Erectile Function (IIEF) for men. Construct validity was assessed via Principal Component Analysis (PCA), and reliability via Cronbach's alpha. Convergent and discriminant validities were evaluated against standard psychometric batteries. Results: Item 2 was removed due to low communality (0.167). PCA on the remaining 9 items revealed a two-factor structure accounting for 72.5% of total variance: Component 1 (Sexual Functioning and Satisfaction, 59.89%) and Component 2 (Partner Devaluation, 12.66%). Internal consistency was high (alpha= 0.911 overall; alpha= 0.841 in women; alpha= 0.899 in men). Qualisex scores correlated strongly with Skindex-29 Social Functioning (r = 0.582) and Emotions (r = 0.531) subscales, as well as FSFI (r = -0.391) and IIEF (alpha= -0.566). Discriminant validity was supported by low-to-moderate correlations with DASS-21 domains (r < 0.38). While FSFI and IIEF showed significant negative correlations with age (p = 0.002), Qualisex remained age-independent across sexes (p > 0.05). Conclusion. The 9-item Italian Qualisex is a reliable, sex-symmetrical, and age-independent patient-reported outcome measure for assessing sexual health impairment in LS, successfully isolating disease-specific distress from physiological aging and general distress.

Frailty assessment is important while awaiting lung transplantation (LTx), as frailty is associated with disability and death before and after LTx. We assessed known risk factors and/or frailty indicators in frail, pre-frail, and non-frail patients according to the Short Physical Performance Battery (SPPB) and the Frailty Instrument for primary care of the Survey of Health, Ageing and Retirement in Europe (SHARE-FI), and evaluated the value of SHARE-FI as a proxy to detect frail patients. Frailty was assessed using SPPB and SHARE-FI in 82 patients on a waiting list for LTx. Demographic, anthropomorphic, and clinical variables were collected, and patients underwent respiratory/cardiorespiratory, biochemical, and quadriceps muscle performance assessments. The mean age was 57.3 {+/-} 9.4 years. Chronic obstructive pulmonary disease (COPD) (41.5%) and interstitial lung disease (ILD) (30.6%) were the most common indications for LTx. Four (4.9%), 13 (15.9%), and 65 (79.3%) patients were classified as frail, pre-frail, and non-frail by SPPB, respectively. These figures were 26 (31.7%), 41 (50%), and 15 (18.3%) with SHARE-FI. SPPB found differences between frail/pre-frail and non-frail patients in physical performance (6-minute walking distance) and muscular assessment, while SHARE-FI found differences in age, 6-minute walking distance, and oxygen saturation, and a trend in muscular strength. For COPD and ILD, frailty discrimination was better with SPPB. Concordance between the two measurements was weak, although all SPPB-frail ILD patients were detected by SHARE-FI. In patients awaiting LTx, SPPB showed better discrimination than SHARE-FI for COPD and ILD. SHARE-FI seems appropriate as a preliminary screening instrument for patients with ILD.

Background: Nigeria introduced single-dose HPV vaccination for girls aged 9-14 in 2023, reaching approximately 60% aggregate coverage by 2025. While an important achievement, this remains short of the 90% coverage called for under the WHO's 90-70-90 cervical cancer elimination targets, and further scale-up depends on reaching out-of-school girls. In this study we used a model of HPV transmission in Nigeria to quantify the residual cervical cancer burden under continued adolescent delivery, assess how additional screening scale-up and equity assumptions modify it, and identify the effective coverage requirements for an infant HPV vaccination program to be non-inferior to the existing adolescent strategy. Methods: We used HPVsim, an agent-based microsimulation calibrated to Nigerian sexual behavior, HPV prevalence, and cervical cancer incidence, to project new cervical cancer cases and age-standardized incidence over 2025-2100 under scenarios which vary vaccination delivery mode (status-quo adolescent, WHO 90-70-90 adolescent scale-up, and 60/75/90% infant delivery), screening coverage (opportunistic 15% vs. scaled 70% aggregate), and the degree to which primary school completion correlated with vaccination (odds ratio 1 vs. 5) and with screening (odds ratio 1 vs. 3). Infant delivery scenarios were run at hypothetical effective-vaccine-efficacy-at-exposure values of 50%, 70%, and 95% - scenario inputs bracketing the plausible waning range, not evidence-based estimates of infant vaccine performance (no HPV vaccine trial has enrolled anyone below age 10). Each scenario was run at 50 replicates (10 calibration draws, 5 seeds); reported outcomes are the median across replicates and uncertainty ranges are interquartile (25th-75th percentile). Results: Continuation of Nigeria's current adolescent program is projected to avert 1.82 million cervical cancer cases (IQR 1.65-1.90 million; 95% UI 1.39-2.02 million) over 2025-2100 (a 53% reduction relative to no vaccination, IQR 51-55%; 95% UI 46-58%), with age-standardized incidence falling from 19.7 to 7.8 per 100,000 by 2100. However, 82% of the near-term (2025-2075) burden is projected to fall on the pre-2015 birth cohort, i.e. women already beyond the vaccination target age, leaving approximately 945,000 residual cases (IQR 905K-1.00M; 95% UI 835K-1.14M) in this cohort. Scaling up screening to WHO targets was estimated to avert a further ~387K cases (IQR 331-424K; 95% UI 269-515K), roughly 25% of the residual burden; results were about 6-8% better if the scale-up instead reached all women equitably regardless of education. Under a hypothetical scenario of infant vaccination at 90% coverage and 95% effective vaccine efficacy at exposure (matching adolescent-age performance), outcomes were comparable to full WHO adolescent scale-up (49% vs. 54% reduction in vaccine-targetable cohort cancers), but under a hypothetical 50% effective efficacy at Nigeria's DTP3-anchored 62% coverage the strategy averted only a fraction of these cancers. Conclusions: The near-term cervical cancer burden in Nigeria is dominated by cohorts vaccination cannot reach; scaling screening for them is the more consequential lever over the coming three decades and rests on established evidence. Findings on infant HPV delivery are exploratory and hypothesis-generating: they depend on three unverified empirical prerequisites - infant HPV vaccine immunogenicity in the first months of life, durability of protection across the ~15-25-year interval to peak HPV exposure, and coverage achievable through Nigeria's routine childhood immunization platform - and should not be read as a basis for any policy recommendation contingent on infant HPV delivery until those prerequisites are established.

Early risk stratification of COVID-19 patients at admission informs triage and resource allocation, particularly in low- and middle-income settings where intensive-care capacity is constrained. Most published models are not interpretable, rarely externally validated, and developed almost exclusively in high-income cohorts. We developed an interpretable random-forest classifier for three-class COVID-19 severity (Mild: not ventilated, survived; Severe: ventilated, survived; Fatal: died) using only data available within 24 hours of admission in 321 hospitalised PCR-confirmed COVID-19 patients in Pakistan. From 2,278 raw variables we retained 20 predictors by clinical screening and permutation-importance selection, with leakage-controlled multiple imputation by chained equations and SHapley Additive exPlanations (SHAP) for interpretation. A 15-feature variant was evaluated in two independent public cohorts: the Chinese iCTCF cohort (n = 894) and an Italian complete-blood-count cohort (n = 1,218). The development model achieved a macro F1 of 0.55, identifying the Fatal class most reliably (F1 0.67, recall 0.73) and Mild cases least well. SHAP identified a parsimonious set of admission-time predictors (oxygen saturation, lactate dehydrogenase, urea, C-reactive protein, age and radiographic pneumonia), including a raised urea-to-creatinine ratio in fatal cases most consistent with dehydration (median urea 80 vs 50 mg/dL, fatal vs mild; p < 0.001). Externally, the model retained useful discrimination in the Chinese cohort (mortality AUC 0.82 in 719 patients with recorded outcomes; severe-or-worse AUC 0.75; macro F1 0.50) but only modest discrimination in the Italian cohort (AUC 0.62, 95% CI 0.56-0.68), which we treat as a feature-availability stress test rather than a second validation. Cross-cohort SHAP rankings correlated strongly in China (Spearman {rho} = 0.91) and moderately in Italy ({rho} = 0.76), where most laboratory predictors were imputed and carried no information beyond the complete blood count; discrimination tracked how many predictors were actually measured. The admission-time signature converges with established markers of hypoperfusion and inflammation.

Stroke is a leading cause of mortality and disability in Uganda, with a prevalence of approximately 2.5% and a 25-30% 30-day mortality rate, exacerbated by limited access to predictive tools and advanced diagnostics. Machine learning (ML) offers potential for early stroke risk stratification, but its application in resource-constrained settings like Uganda requires tailored models and rigorous performance evaluation, as well as assessment of misclassification patterns. This study aimed to develop and internally validate an ML-based predictive model for stroke using clinical and socio-demographic characteristics among patients at Mulago National Referral Hospital (MNRH) and residents of Wakiso District, Uganda, identify key predictors and assess misclassification patterns to enhance targeted prevention. A retrospective case-control study utilized secondary data from 1,016 participants (254 stroke cases, 762 controls) across three prior studies conducted between 2006 and 2015. Eight ML algorithms were evaluated using 5-fold cross-validation, with performance metrics including accuracy, sensitivity, positive predictive value, F1-score, and area under receiver operator characteristics curve (AU-ROC). McNemars test compared model classification performance of the top 2 models. Feature importance identified key predictors, and misclassification patterns were analyzed using classification matrix and line graphs. The Random Forest (RF) model achieved the highest performance (95.18% accuracy, 90.10% F1-score, 97% AU-ROC). McNemars test confirmed RFs superior classification (p=0.01). Age, systolic blood pressure, total cholesterol, and waist-hip ratio were the top drivers of RF stroke predictions. RF misclassified 8.3% of stroke cases and 3.3% of non-stroke cases, due to overlaps in risk profiles (e.g., lower cholesterol, systolic blood pressure and age in false negatives). The RF model demonstrates strong potential for stroke risk prediction in Uganda, leveraging routine data to prioritize high-risk individuals. Misclassification analysis highlights areas for model refinement, supporting its potential for integration into clinical workflows for early intervention and stroke prevention in resource-limited settings. Future external validation across diverse populations is recommended.

Disability is an important population-health concern, but adult-specific evidence on its distribution and socioeconomic patterning remains limited in Somaliland. This study estimated the prevalence and distribution of reported disability among adults in Somaliland and examined socioeconomic inequality, reported mental/psychological illness, and their co-occurrence. We conducted a cross-sectional secondary analysis of the 2020 Somaliland Health and Demographic Survey. The analysis included 14,579 adults aged [&ge;]18 years who were usual residents, had the disability module administered, and had a defined reported mental/psychological illness measure. Reported disability was defined as at least one positive response across seven disability domains: sight, hearing, speech, learning, mobility, self-care, and mental. Survey-weighted prevalence estimates and design-based comparisons were calculated. Survey-weighted logistic regression assessed associations with household wealth and other covariates. Socioeconomic inequality was assessed using a concentration index and the normalized Erreygers concentration index. Co-occurrence was evaluated by comparing observed joint prevalence with that expected under statistical independence and by survey-weighted logistic regression. The survey-weighted prevalence of any reported disability was 7.30% (95% CI 6.65-8.02). Sight was the most frequently reported domain (3.83%, 95% CI 3.19-4.59), followed by hearing (1.54%, 95% CI 1.20-1.97) and mobility (1.39%, 95% CI 1.14-1.70). Disability prevalence increased markedly with age, from 4.15% among adults aged 18-29 years to 23.96% among those aged [&ge;]60 years. The crude wealth pattern was non-monotonic and was not statistically detectable after adjustment for residence and region. The concentration index for reported disability was 0.0584 (SE 0.0284, p=0.0415). Reported mental/psychological illness had a weighted prevalence of 0.71% (95% CI 0.50-1.00). Both reported disability and reported mental/psychological illness occurred in 0.5032% of adults, compared with 0.05185% expected under statistical independence; the observed-to-expected ratio was 9.70 (95% CI 7.60-11.81). After adjustment for age group and sex, reported disability was strongly associated with reported mental/psychological illness (OR 42.99, 95% CI 18.45-100.18). Reported disability affected approximately one in fourteen adults in Somaliland and showed a marked age gradient and substantial geographic variation. The crude socioeconomic pattern was attenuated after adjustment for geographic context, while concentration analysis indicated modest marginal concentration toward higher wealth ranks. Reported mental/psychological illness was uncommon but co-occurred with reported disability more often than expected under independence. These findings provide an adult population baseline for Somaliland while highlighting the need to distinguish survey-reported disability from the separate mental/psychological illness construct and to interpret the findings within the limitations of cross-sectional, survey-reported measures.

Nicotinamide riboside (NR), a precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+), has been extensively studied following oral administration, while the longer-term safety and physiological effects of injectable NR remain less characterized. Following an initial in-clinic phase evaluating repeat intramuscular (IM) and subcutaneous (SC) administration of pharmaceutical-grade NR, participants transitioned to an at-home phase designed to assess the safety, feasibility, and exploratory physiological effects of repeated self-administered SC administration. Participants continued their assigned 50 or 100 mg dose group and self-administered NR subcutaneously 3 times weekly for approximately 90 days. Safety was assessed through adverse event (AE) monitoring, vital signs, and clinical laboratory health measures. Exploratory assessments included markers of mitochondrial bioenergetics, urinary biomarkers of oxidative stress, and participant-reported outcomes related to fatigue, sleep, pain, and quality of life. At-home administration of NR was generally well-tolerated, with no clear dose-dependent safety concerns identified over the study period. Further, participants were able to successfully self-administer repeated SC injections over the study period, demonstrating positive feasibility. Whole-blood NAD+ concentrations remained largely stable over time in both dose groups. MeScreen analysis demonstrated a reduction in GlycoATP at Day 30 and increases in the MitoATP/GlycoATP ratio at Day 30 and Day 90, signifying a preferential shift toward oxidative metabolism. These findings may be indicative of positive metabolic health shifts. Urinary oxidative stress profiling demonstrated heterogeneous temporal responses. Several lipid oxidation markers significantly declined at Day 30 but returned toward baseline at Day 90. Select markers of nucleic acid, nitrative stress, and advanced glycation end-product oxidation demonstrated more sustained reductions. These results for which the majority of measured oxidative stress markers improved suggest that NR injections may exhibit anti-oxidative characteristics. Validated participant-reported sleep and fatigue measures showed improvements. Self-reported facial skin improvement increased descriptively from 11.4% at baseline to 27.8% at Day 30 and 36.8% at Day 90; improvements noticed by others increased from 9.1% to 23.7%, while reported body-skin improvement increased more modestly, from 8.8% to 16.7%. As these outcomes were not designed or powered to establish efficacy or definitive clinical claims, the findings should be considered hypothesis generating and provide preliminary data to inform the selection of outcomes and design considerations for future randomized, placebo-controlled, adequately powered trials of SC NR administration.

Objective Reducing household air pollution exposure during gestation and infancy may have longer-term benefits for child linear growth. We examined whether a liquefied petroleum gas (LPG) cookstove and fuel intervention delivered during gestation and infancy could improve height-for-age Z scores (HAZ) and reduce the risk of stunting at ages 2-5 years in India, Rwanda, and Guatemala. Materials and method The Household Air Pollution Intervention Network (HAPIN) was a randomized controlled trial that enrolled ~3200 pregnant women across Guatemala, India, Peru, and Rwanda. Women in the intervention group received an LPG cookstove and free fuel during pregnancy and until the infant reached 12 months of age. Following the HAPIN trial, we continued following children in Guatemala, India, and Rwanda (N=2169) and measured child height at ages 2, 3, 4, and 5 years (HAPIN 2.0). As prespecified in the study protocol, we used mixed-effects models, as well as linear and log-binomial regression, within the intention to treat (ITT) framework, to evaluate the interventions effect on HAZ and stunting. Subgroup analyses were performed to assess effect modification by child sex, maternal height, and intervention country. Results The intervention reduced gestational exposures to particulate matter (PM2.5: 80.7 vs 117.5 {micro}g/m3), carbon monoxide (CO: 1.3 vs 2.0 ppm), and black carbon (BC: 8.6 vs 12.1 {micro}g/m3) and infancy exposures (PM2.5: 36.9 vs 113.2 {micro}g/m3; CO: 0.60 vs 2.2 ppm). Post-trial PM2.5 exposure were similar between arms: 99.9 vs 98.7 {micro}g/m3. We found no statistically significant effect of the intervention on repeated measures of HAZ ({beta} = -0.06, 95% CI: -0.16, 0.03 p=0.204), annual HAZ, stunting, nor severe stunting at any age during the follow-up. There was no statistically significant effect modification by subgroups. Conclusion Despite substantial reductions in air pollution exposures during the trial, the LPG intervention did not improve growth or reduce stunting risk from ages 2 through 5 years in this multi-country cohort. These findings, consistent with prior results of the lack of effects on growth through 12 months, provide additional evidence that a clean cooking intervention alone may not be sufficient to address childhood stunting in low-resource settings. Future exposure-response analyses will supplement these ITT analyses.

Objectives To describe active surveillance (AS) outcomes following introduction of an MRI-informed pathway, examine whether baseline PI-RADS/Likert scores identify men with earlier AS discontinuation, and assess the acceptability of dietary fibre supplementation in men on AS. Patients and methods We conducted a retrospective audit of 420 men enrolled in AS at Aberdeen Royal Infirmary between 2012 and 2022. Men were grouped into an MRI-informed pathway (n=198) or biopsy-first pathway (n=222). Time to AS discontinuation for any reason was analysed using Kaplan-Meier methods and log-rank tests. An exploratory analysis compared men with baseline PI-RADS/Likert scores of 4-5 and 2-3. Ten men on AS also completed semi-structured interviews analysed using the Theoretical Framework of Acceptability. Results Median follow-up was 3.1 years (IQR 1.6-5.1). Overall, 208 men (49.5%) discontinued AS, including 176 because of disease progression. Median time to discontinuation was 4.9 years (95% CI 4.4-5.6). It was shorter in the MRI-informed pathway than in the biopsy-first pathway (4.1 vs 5.6 years; log-rank p<0.01). Among 167 men with recorded baseline MRI scores, 44 (26.3%) had PI-RADS/Likert 4-5. Median time to discontinuation was 2.9 years in this group compared with 4.0 years for scores 2-3 (p<0.01). Interview participants were generally willing to consider dietary fibre supplementation, although gastrointestinal effects and study procedures were anticipated burdens. Conclusion AS discontinuation occurred earlier in the MRI-informed pathway, although differences in patient selection and surveillance practice should be considered when interpreting this finding. PI-RADS/Likert 4-5 identified a sizeable subgroup with earlier all-cause AS discontinuation that may help inform recruitment to future intervention studies. Dietary fibre supplementation was acceptable in principle, supporting further feasibility work.

BACKGROUND: Adverse consequences of neonatal hyperbilirubinemia disproportionately affect babies in low- and middle-income countries. Laboratory measurement of total serum bilirubin is limited in low-resource settings, necessitating simpler alternatives. Our study aimed to evaluate the diagnostic accuracy of visual inspection of jaundice via the World Health Organization Integrated Management of Childhood Illnesses algorithm compared to transcutaneous bilirubinometry for the identification of hyperbilirubinemia in community settings. METHODS: Hyperbilirubinemia was assessed by visual inspection for jaundice and transcutaneous bilirubinometry at 0-72 hours, 3-5 days, and 5-14 days postnatal in the PRISMA prospective cohort study in six sites in Asia and Africa. We assessed sensitivity, specificity, and positive and negative percent agreement. RESULTS: We analyzed data from 14,331 infants, including 1,852 preterm infants. 15% had hyperbilirubinemia, as defined by transcutaneous bilirubin values and the NICE nomograms, at 3-5 days postnatal. Visual inspection had a sensitivity of 16%, specificity of 96%, positive percent agreement of 56%, and negative percent agreement of 86% at 3-5 days postnatal age, pooled across all sites and gestational ages, versus transcutaneous bilirubin defined by NICE nomograms. CONCLUSION: The poor sensitivity of visual inspection underscores an urgent need for accurate, affordable screening tools to improve screening for hyperbilirubinemia.

Nurse-led skin cancer screening extends specialist reach but depends on the nurse selecting which lesions to forward for diagnosis, and performance varies with experience. We evaluated whether real-time decision support using artificial intelligence (AI) improves malignancy detection in routine nurse-led teledermoscopy screening across MoleMap clinics in New Zealand and Australia (January 2024-July 2025). In this real-world study, clinics using AI decision support were compared with standard clinics. Nurses examined patients, captured dermoscopic images, and forwarded selected lesions to teledermatologists, who provided the reference diagnosis. The analytic cohort comprised 1,102,382 lesions from 98,422 patients across 577 sites. AI-assisted screening was associated with a higher malignancy detection rate than standard screening (25.5 vs 15.7 malignancies per 1,000 lesions; odds ratio adjusted for nurse experience 1.73, 95% CI 1.68-1.77), a finding consistent across all nurse-experience tiers and the three major malignant subtypes. AI assistance was also associated with a shift in recommended management: 21 additional intervention recommendations and 13 additional safety-netting recommendations (self-monitoring, short-term follow-up, or specialist referral) per 1,000 lesions, approximately balanced by 34 fewer no-action recommendations. The reference standard was teledermatologist diagnosis and allocation was not randomised; findings are therefore associational and require prospective, outcome-based confirmation.

Background/Aims This work aimed to estimate the annual tertiary healthcare and societal costs associated with paediatric congenital heart disease (CHD) in the United Kingdom using real-world data from a Level 1 cardiac surgical centre in the National Health Service (NHS). Methods A prevalence-based cost-of-illness analysis was conducted using patient-level inpatient and outpatient activity data from Evelina London Children's Hospital between 1 June 2023 and 31 May 2024. Costs were estimated from NHS and societal perspectives and extrapolated to national level using National Congenital Heart Disease Audit (NCHDA) procedural activity data. Healthcare costs included tertiary centre care costs. Societal costs included parental productivity losses and impacts on lifetime earnings for children. Deterministic sensitivity analysis explored parameter uncertainty. Results Approximately 9.6% of UK paediatric CHD procedures were undertaken at Evelina London Children's Hospital at a cost of {pound}15.0 million per annum, corresponding to a national estimate of {pound}156.4 million. Single-ventricle procedures accounted for 4.8% of inpatient activity but 19.4% of inpatient costs. Sensitivity analysis produced national healthcare cost estimates ranging from {pound}125.1 million to {pound}187.7 million. National productivity losses associated with parental absence from work were estimated at {pound}82.4 million annually. Individuals with CHD were estimated to experience a mean reduction in lifetime earnings of {pound}81,509. Conclusion Paediatric CHD imposes a substantial economic cost on the UK healthcare system and wider society. This study provides the first real-world national estimate of the economic impact of paediatric CHD in the UK and may inform future service planning, research investment, and innovation adoption strategies.

Background: Self-supervised learning may improve segmentation when labelled data are limited, but its benefit may depend on model and initialisation strategy. This study evaluated in-domain masked-reconstruction pretraining across limited annotation budgets. Methods: The International Skin Imaging Collaboration (ISIC) 2016 development set was partitioned into 765 images for self-supervised pretraining, 94 for fine-tuning and 41 for validation. Five nested annotation budgets (12-94 images) and five seeds were evaluated on the 379-image test set. A custom U-Net compared random and in-domain self-supervised initialisation; a ResNet-34 U-Net compared random, ImageNet, in-domain self-supervised and sequential ImageNet-to-self-supervised initialisation. Models trained with 94 labelled images were evaluated without adaptation on ISIC 2017. A separate experiment examined restoration-based pretraining. Results: In the custom U-Net, self-supervised pretraining achieved higher mean Dice than random initialisation at all five budgets, including 0.664 versus 0.615 with 12 labels and 0.811 versus 0.768 with 94 labels. Seed-level 95% confidence intervals for paired differences excluded zero at 47 and 94 labels but not at the other budgets. With 47 labels, the self-supervised model achieved mean Dice of 0.789, compared with 0.768 for random initialisation with 94 labels. In ResNet-34, ImageNet initialisation achieved higher mean Dice than in-domain self-supervised pretraining at all five budgets, and adding self-supervised pretraining after ImageNet reduced mean Dice at four of five budgets. All six 94-label configurations achieved lower mean Dice on ISIC 2017 than ISIC 2016. In the restoration experiment, mean Dice was 0.686 with random initialisation and 0.638-0.642 following pretraining. Conclusions: In-domain masked-reconstruction pretraining improved mean Dice relative to random initialisation in the custom U-Net, but not consistently in the ResNet-34 U-Net, where ImageNet initialisation performed better at every budget. Adding self-supervised pretraining after ImageNet provided no consistent gain. These findings are specific to the dermoscopic lesion-segmentation experiments and do not establish melanoma-specific diagnostic or clinical performance.